SS Innovations International Inc. has expanded the clinical reach of its SSi Mantra surgical robotic system with the launch of a robotic cardiac surgery program at HCG Hospital in Ahmedabad, India. The program commenced with a robotic left internal mammary artery (LIMA) take-down performed by Dr. Brajmohan Singh and proctored by Dr. Lalit Malik. This procedure, using the SSi Mantra 3.0 system, represents a significant step in demonstrating the system's capabilities in cardiac surgery, a complex and high-stakes specialty.
The expansion matters because it adds a new cardiac program to the SSi Mantra's clinical footprint, potentially increasing adoption among hospitals seeking advanced robotic options. As of September 8, SS Innovations reported 238 SSi Mantra systems installed, a 42% increase from the end of 2025. The system is now installed in 12 countries, with recent entries into Colombia, Sri Lanka, and the Philippines. This growth trajectory suggests accelerating market acceptance and could drive revenue growth for the company, which trades on NASDAQ under the ticker SSII.
For investors, the news signals execution on the company's strategy to broaden its global presence. SS Innovations is pursuing U.S. FDA review and European Union CE marking, aiming to enter additional international markets. Success in these regulatory efforts could unlock substantial new opportunities, particularly in the U.S. and Europe, where robotic surgery adoption is high. The new cardiac program at HCG Hospital may also serve as a reference site, encouraging other hospitals to adopt the SSi Mantra for cardiac procedures.
The company's LinkedIn post highlighted the achievement, congratulating the surgical team and reaffirming its commitment to enabling hospitals. More details are available in the company's newsroom at https://ibn.fm/SSII. The announcement was distributed via InvestorWire, a communications platform that is part of the Dynamic Brand Portfolio at IBN. InvestorWire provides services including editorial syndication to 5,000+ outlets and social media distribution.
As SS Innovations continues to expand, the new cardiac program in Ahmedabad could pave the way for further installations in India and beyond. The company's focus on regulatory milestones and international expansion positions it for potential long-term growth, though it faces competition from established players in the robotic surgery market. Investors will be watching for updates on FDA and CE progress, as well as additional clinical programs that demonstrate the versatility of the SSi Mantra system.
